Stockholders elect director, ratify auditor, approve 2023 equity plan

MEDICINOVA INC

Hideki Nagao elected Class I director with 19.7M for, 7.5M against, 1.4M abstain, 2.7M broker non-vote.
BDO USA, LLP ratified as independent auditor for fiscal 2023: 27.8M for, 2.4M against, 1.1M abstain.
2023 Equity Incentive Plan approved: 19.2M for, 7.9M against, 1.5M abstain, 2.7M broker non-vote.
Meeting held June 13, 2023; 31.3M shares voted of 49.0M outstanding (quorum present).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MEDICINOVA INC shareholders approved Approve the Company’s 2023 Equity Incentive Plan, as disclosed in the Proxy Statement. at the 2023-06-13 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

To approve the Company’s 2023 Equity Incentive Plan, as disclosed in the Proxy Statement. This proposal was approved, with the votes thereon at the Annual Meeting as follows: Final Voting Results For Against Abstain Broker Non-Vote 19,200,437 7,879,289 1,504,082 2,715,513

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MEDICINOVA INC shareholders approved Ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. at the 2023-06-13 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

To ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. This proposal was approved, with the votes thereon at the Annual Meeting as follows: Final Voting Results For Against Abstain Broker Non-Vote 27,807,178 2,362,900 1,129,243 -

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MEDICINOVA INC shareholders approved Election of one Class I Director nominee named below to serve until the 2026 Annual Meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until their earlier death, resignation or removal. at the 2023-06-13 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

To elect one Class I Director nominee named below to serve until the 2026 Annual Meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until their earlier death, resignation or removal. The named nominee was so elected, with the votes thereon at the Annual Meeting as follows: Final Voting Results Nominees For Against Abstain Broker Non-Vote Hideki Nagao 19,685,986 7,517,392 1,380,430 2,715,513

View on SEC.gov

Browse all shareholder votes →

MEDICINOVA INC filing history →

Source: SEC EDGAR

accession 0000950170-23-027823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.